BBCancer: an expression atlas of blood-based biomarkers in the early diagnosis of cancers

Zhixiang Zuo†, Huanjing Hu†, Qingxian Xu, Xiaotong Luo, Di Peng, Kaiyu Zhu, Qi Zhao*, Yubin Xie* and Jian Ren*

State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University, Guangzhou 510060, China

Received August 15, 2019; Revised September 28, 2019; Editorial Decision October 07, 2019; Accepted October 09, 2019

ABSTRACT

The early detection of cancer holds the key to combat and control the increasing global burden of cancer morbidity and mortality. Blood-based screenings using circulating DNAs (ctDNAs), circulating RNA (ctRNAs), circulating tumor cells (CTCs) and extracellular vesicles (EVs) have shown promising prospects in the early detection of cancer. Recent high-throughput gene expression profiling of blood samples from cancer patients has provided a valuable resource for developing new biomarkers for the early detection of cancer. However, a well-organized online repository for these blood-based high-throughput gene expression data is still not available. Here, we present BBCancer (http://bbcancer.renlab.org/), a web-accessible and comprehensive open resource for providing the expression landscape of six types of RNAs, including messenger RNAs (mRNAs), long noncoding RNAs (lncRNAs), microRNAs (miRNAs), circular RNAs (circRNAs), tRNA-derived fragments (tRFs) and Piwi-interacting RNAs (piRNAs) in blood samples, including plasma, CTCs and EVs, from cancer patients with various cancer types. Currently, BBCancer contains expression data of the six RNA types from 5040 normal and tumor blood samples across 15 cancer types. We believe this database will serve as a powerful platform for developing blood biomarkers.

INTRODUCTION

The early detection of cancer can greatly reduce the probability of distal metastasis, thereby improving the survival rate of cancer patients (1). The measures of early detection include screening of cancer cells or tissues before symptoms are present and recognizing early symptoms before cancer progression. While a number of methods for early detection of cancer are proposed, only a handful of cancer screening methods are shown to be effective in the clinic. In recent years, liquid biopsy methods (mainly blood-based tests) for the early detection of cancer have received much attention (2). The data on blood-based tests are promising, but the specificity and sensitivity are still challenging (3,4). An ideal set of biomarker molecules and effective algorithms are needed to develop an accurate blood-based testing method.

Current blood-based tests mainly focused on molecules, such as circulating tumor DNAs (ctDNAs), with DNA fragments released by tumor cells or tissues into the blood circulating system, since these molecules could survive long in blood and contain genetic changes identical to the tumors they derive from. Genetic changes in ctDNAs, such as mutations, copy number changes, gene fusion events, and even DNA methylation patterns, have been widely investigated as biomarkers in blood-based tests. For instance, mutations in the ER gene can be frequently found in ctDNAs of breast cancer patients and can potentially be used as a biomarker to predict the response of endocrine therapy (5). Patients with innate trastuzumab resistance presented high HER2 copy number alterations in ctDNAs from HER2-positive gastric cancer patients (6). Xu et al constructed a prediction model based on ctDNA methylation for the diagnosis of hepatocellular carcinoma with high diagnostic specificity and sensitivity (7).

In contrast, RNA molecules have not received much attention as biomarkers for the early detection of cancers, since RNA molecules are unstable in the circulating system. However, an increasing number of studies have indicated that RNA molecules, such as microRNAs (miRNAs), circular RNAs (circRNAs), tRNA-derived fragments (tRFs) and Piwi-interacting RNAs (piRNAs), are frequently detected in human blood (8–11), suggesting the promising prospect of these RNA molecules as biomarkers for blood-
based tests in early cancer detection. Moreover, extracellular vesicles (EVs) and circulating tumor cells (CTCs) in the blood play fundamental roles in cancer progression. The coding and noncoding RNA molecules present in EVs and CTCs could potentially be used as biomarkers in blood-based tests.

Advances in high-throughput technologies, such as microarrays and next-generation RNA sequencing (RNA-Seq), have resulted in large amounts of gene expression data of blood samples across different cancer types. Some databases based on the integration of high-throughput data analysis have emerged in recent years. Kim et al. constructed EVpedia (12), a useful resource to elucidate the fundamental roles of EVs derived from prokaryotes and eukaryotes from 130 high-throughput sequencing studies. Li et al. developed exoRBase that contains 58,330 circRNAs, 15,501 lncRNAs and 18,333 mRNAs from 87 blood exosomal RNA-seq datasets (13). Nevertheless, a comprehensive online repository for these blood-based high-throughput gene expression data specialized for the early detection of cancer is still lacking.

Here, we present BBCancer (http://bbcancer.renlab.org/), a web-accessible and comprehensive open resource for providing the expression landscape of six RNA types, including mRNAs, lncRNAs, miRNAs, circRNAs, tRFRNAs and piRNAs in blood samples, including plasma, CTCs and EVs, from cancer patients with various cancer types (Figure 1). Using BBCancer, users are able to evaluate the expression abundance of RNAs of interest in tumor and normal blood samples from different cancer types. Moreover, users can explore the differential expression of RNAs of interest between tumor and normal blood samples. We believe that BBCancer will serve as a powerful platform for developing blood-based biomarkers for the early detection of cancers.

MATERIALS AND METHODS

Data sources

The RNA-seq and gene expression microarray raw datasets were collected from NCBI SRA (14) and GEO (15) databases. We queried the SRA and GEO databases using both cancer-related key words and blood-related key words. The SRA files from the SRA database were downloaded by the Aspera high-speed file transfer protocol (http://asperasoft.com/) and were converted to FASTQ files by using SRA Toolkit (SRA Toolkit Development Team, http://ncbi.github.io/sra-tools/). Sample information, such as tissue types (tumor or normal), was collected and manually curated. We also downloaded the probe sequences of each microarray platform from the GEO database or the websites of their corresponding companies for the purpose of reannotating the probes. All collected datasets were limited to human studies. Currently, all datasets were collected before July 2018.

Analysis of RNA-seq data

All collected RNA-seq datasets were processed using the following pipeline. Briefly, FastQC was used to check the quality of raw sequencing data in the FASTQ format. The raw sequencing reads were trimmed by removing adapters and low-quality bases using Cutadapt (v. 1.7.1) (16). For long RNAs, the trimmed sequencing reads were mapped to the human reference genome (GRCh38) using HISAT2 (v. 2.0.4) (17). HTSeq-count (v. 0.6.0) (18) was employed to quantify the number of reads aligned to regions of mRNAs or lncRNAs. Read counts for each gene were normalized to the RPKM values (Reads Per Kilobase per Million mapped reads) (19). CircRNAs were identified using CIRI (v. 2.0.5) (20) and find_circ (v. 1.2) (21). Only circRNAs that were identified by either of the two tools were retained. Read counts for each circRNA were normalized by calculating the RPM values (Read counts per million mapped reads). For miRNAs and piRNAs, all of the small sequencing reads were aligned to the miRBase (v. 22) and piRNA-Bank (22) using a BLAST-like alignment tool (BLAT) (23). Only alignments with no more than one mismatch, no gaps and a mapping length equal to the length of the small RNA were considered as the best match. The raw counts of miRNAs and piRNAs were normalized to RPM values (24). For tRFRNAs, all of the small sequencing reads were analyzed using MINTmap (v. 1.0) (25) and MINTbase (26) to identify and quantify tRFRNAs.

Analysis of gene expression microarray data

Previous studies have shown that the probes of many protein-coding gene expression microarrays should be reannotated to lncRNAs according to the latest gene annotation files. We used the following strategy to reannotate the probes from different gene expression microarray platforms. The latest gene annotation files were downloaded from the ENSEMBL database. A BLAST-like alignment tool (BLAT) (27) was used to align all probe sequences from the different microarray platforms to the human genome (GRCh38). Only alignments with no more than one mismatch, no gaps and a similarity score larger than 90 bp were retained. In general, probes (50–60 nucleotides) from Agilent and Illumina platforms were designed to locate target genes or transcripts. The microarrays from Affymetrix utilized a probe set containing a group of 25-mer probes to represent a gene or transcript. Thus, for Affymetrix data, we combined probes that specifically corresponded to the same probe set and ensured that there were at least three perfectly matching and adjacent probes in each probe set. Second, we mapped the probes to coding genes or lncRNAs according to their genomic coordinates. If any probes were targeted to both coding genes and lncRNAs, then we only preserved the annotation of the coding genes. MicroRNA probes were uniformly annotated by miRBase (v.22).

The following strategy of gene expression was applied to the diverse microarray platforms within BBCancer. First, the raw data were normalized using different methods according to the different platforms. For Agilent, Illumina and other platforms, the ‘Limma’ package (28) was employed to quantile-normalize the data sets. For the Affymetrix GeneChip data, raw CEL files were normalized with the RMA algorithm (‘affy’ package v. 1.26 or ‘appt-probeset-summarize’ in Affymetrix Power Tools v. 1.19.0) (29,30). For certain studies lacking raw data, we used the data matrix provided in the GEO database as a normalized expression matrix. The expression of each gene was
log₂ transformed. Next, all of the probes were transformed to gene names based on the above re-annotation file. The average expression was calculated to represent those genes that are targeted by multiple probes. Finally, a robust rank aggregation algorithm was utilized to integrate the rank of gene expression abundance from multiple datasets for the same cancer type.

Differential expression analysis

We categorized differential expression with one of the following conditions: tumor versus normal, precancerous lesion versus normal and precancerous lesion versus tumor. For RNA-Seq and microarray data, differential expression analysis was performed with the ‘DESeq2’ (31) and ‘Limma’ package (32), respectively. Finally, a robust rank aggregation algorithm was utilized to integrate the blood-based RNA profiles in an unbiased manner (33). The aggregation rank score (AR score) represents the integrated rank from the meta-analysis of the fold-changes in different studies. All results were scaled by cancer type and presented in a heat map, allowing users to interactively explore the expression of RNAs of interest.

Database and web interface implementation

All data in BBCancer were stored and managed by MySQL tables. The web interfaces were implemented in Hyper Text Markup Language (HTML), Cascading Style Sheets (CSS) and JavaScript (JS). To visualize the analysis results, multiple statistical diagrams were embedded in the website. The interactive heat maps showing the expression abundance and differential expression were constructed by DataTables. The charts presenting gene expression rank and the boxplots showing the differential expression were drawn by Highcharts. Furthermore, all analyses in the BBCancer website were performed in R.

RESULTS

Database content

In the current release, BBCancer contains expression data for RNA molecules from 7,184 samples, including 5,040 blood samples such as extracellular vesicles (EVs) and circulating tumor cells (CTCs), in normal person and 15 cancer types including breast cancer, borderline ovarian tumor, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, and prostate cancer (Table 1). Six types of RNA (19 612 miRNAs, 10 918 IncRNAs, 60 306 circRNAs, 2568 miRNAs, 1231 piRNAs and 43 459 tRFRNAs) were included in BBCancer (Table 2). To our knowledge, BBCancer represents the largest blood sample resource for cancer biomarker research.

Web interface and usage

BBCancer provides a user-friendly web interface that contains four modules: Explore, Browse, Statistics and Download.
Table 1. Summary of the gene expression data of samples collected in BBCancer

| Extracellular vesicles | Circulating tumor cells | Other blood | Tumor tissue | Normal tissue | Precancerous tissue |
|------------------------|-------------------------|-------------|--------------|---------------|---------------------|
| Borderline ovarian tumor | 0                       | 0           | 66           | 0             | 0                   |
| Breast cancer          | 42                      | 112         | 171          | 463           | 149                 |
| Colorectal cancer      | 215                     | 6           | 149          | 113           | 271                 |
| Esophageal cancer      | 28                      | 0           | 88           | 117           | 118                 |
| Gastric cancer         | 0                       | 0           | 115          | 22            | 31                  |
| Glioblastoma           | 41                      | 0           | 0            | 18            | 69                  |
| Liver cancer           | 21                      | 0           | 81           | 68            | 77                  |
| Lung cancer            | 3                       | 0           | 123          | 47            | 39                  |
| Multiple myeloma       | 10                      | 0           | 9            | 53            | 67                  |
| Ovarian cancer         | 0                       | 0           | 320          | 8             | 4                   |
| Pancreatic cancer      | 36                      | 24          | 115          | 20            | 5                   |
| Sarcoma                | 0                       | 0           | 115          | 19            | 4                   |
| Wilms' tumor           | 0                       | 0           | 15           | 60            | 4                   |
| Prostate cancer        | 59                      | 0           | 0            | 29            | 128                 |
| Renal cell carcinoma   | 41                      | 0           | 0            | 18            | 63                  |
| Normal person          | 167                     | 25          | 2843         | NA            | 0                   |

Table 2. Summary of the gene number for different RNA types in blood samples in BBCancer

| mRNA | lncRNA | circRNA | miRNA | piRNA | tRFRNA |
|------|--------|---------|-------|-------|--------|
| Breast cancer | 17 313 | 6036 | 0 | 40 564 | 2467 | 765 | 1905 |
| Colorectal cancer | 19 307 | 5791 | 40 564 | 2483 | 374 | 32 623 |
| Glioblastoma | 16 557 | 6818 | 0 | 2310 | 0 | 0 |
| Lung cancer | 17 237 | 528 | 0 | 2310 | 0 | 0 |
| Liver cancer | 16 903 | 4894 | 54 481 | 1630 | 0 | 0 |
| Prostate cancer | 0 | 0 | 0 | 971 | 176 | 23 580 |
| Pancreatic cancer | 17 286 | 6417 | 41 105 | 1958 | 114 | 9289 |
| Multiple myeloma | 0 | 0 | 0 | 1302 | 528 | 10 838 |
| Renal cell carcinoma | 0 | 0 | 0 | 1732 | 214 | 13 953 |
| Sarcoma | 0 | 0 | 0 | 1634 | 0 | 0 |
| Wilms' tumor | 0 | 0 | 0 | 1198 | 0 | 0 |
| Borderline ovarian tumor | 0 | 0 | 0 | 1634 | 0 | 0 |
| Esophageal cancer | 0 | 0 | 0 | 1634 | 0 | 0 |
| Gastric cancer | 0 | 0 | 0 | 1634 | 0 | 0 |
| Ovarian cancer | 0 | 0 | 0 | 1634 | 0 | 0 |
| Normal person | 19 245 | 3385 | 39 358 | 2568 | 400 | 28 581 |

Explore. In BBCancer, six RNA types, including mRNA, lncRNA, circRNA, piRNA, miRNA and tRFRNA, were provided (Figure 2A). An ideal blood biomarker requires two characteristics: distinguishable and detectable. First, the presence of biomarkers in cancer patients should be distinguished from that in normal persons. In BBCancer, we implemented a module, named ‘Differential expression’, to help users find biomarker candidates with such characteristics. The ‘Differential expression’ module allows users to explore the differential expression of RNA of interest between tumor and normal blood samples by an interactive meta-score heat map (Figure 2B). Another desired characteristic of an ideal biomarker is detectable. For this end, we implemented a module, named ‘Expression abundance’, to help users evaluate the expression abundance of an RNA of interest. In the ‘Gene expression abundance’ module, an interactive heat map was implemented to present the meta-score from differential studies for the same cancer type (Figure 2B). In the interactive heat maps of the two modules, a selection box was provided to help users quickly locate cancers, and a text box was provided to allow users to search RNAs of interest (Figure 2B). Furthermore, users can sort the RNAs by clicking the column name. The detailed information for an RNA of interest in a certain cancer was shown when clicking the ‘meta-score’ box. In the detailed information page, gene expression rank line graphs were provided to show the expression abundance of the selected RNAs in all datasets categorized as normal blood samples, tumor blood samples, normal tissues, tumor tissues and precancerous tissues (Figure 2C). In addition, a table embedded with boxplots was provided to show the differential expression of the selected RNAs in different studies, including comparisons between tumor blood samples and normal blood samples, tumor tissue samples and normal tissue samples, and precancerous tissue samples and normal tissue samples (Figure 2D).

Browse. BBCancer systematically categorized the known blood biomarker by ‘Biomarker categories’, ‘Biomarker’, ‘Gene Description’ and ‘Cancer Type’ (Figure 2E). Users are allowed to explore the blood molecular marker of interest to obtain the results of gene expression abundance and differential expression analysis.

Statistics. Detailed statistics on the data in BBCancer were provided in the ‘Statistics’ module.

Download and Help. All data in the database can be downloaded from the ‘Download’ page, and a detailed introd
Figure 2. A schematic workflow of the search interface in BBCancer. (A) BBCancer contains six types of RNAs (mRNA, IncRNA, circRNA, miRNA, piRNA and tRF-RNA). (B) An interactive heat map showing the meta score of the gene expression fold change for each RNA type between tumor blood samples and normal blood samples from different studies for each cancer type (upper panel), and an interactive heat map showing the meta score of the gene expression rank for each RNA type in tumor and normal blood sample for each cancer type (lower panel). (C) Snapshot of the search results for ‘TIMP1’ using the ‘Protein coding’ search mode. Detailed information on the expression abundance of TIMP1 in all the colorectal cancer datasets is shown in the gene expression rank line graphs. (D) The expression of RNA in different studies of colorectal cancer compared to normal tissues. Click the ‘view’ button to obtain the boxplot representing the differential expression of RNAs between different conditions. (E) Interactive table for browsing the known blood biomarkers collected from Uttle et al (34).

Systematical screening of potential blood biomarkers using BBCancer

We next systematically evaluated the utility of BBCancer in discovering potential blood biomarkers for the early detection of cancer. To this end, we first explored the differentially expressed RNAs between tumor and normal blood samples across various cancer types, which resulted in 8646 mRNAs, 296 IncRNAs, 1124 circRNAs, 2401 miRNAs, 160 piRNAs and 6935 tRF-RNAs (Figure 3A, fold change >1.5, adjusted P-value <0.05). A number of RNAs were differentially expressed in more than five types of cancers, suggesting broad pancancer functional importance of these RNAs (Figure 3B). Uttle et al. identified 788 potential blood biomarkers covering 13 cancer types based on a comprehensive investigation of 3990 related papers (34). We examined the expression pattern of these 788 potential biomarkers across different cancer types in BBCancer.

Among the 788 biomarkers, 314 have expression data in BBCancer. We found that 144 (82 mRNAs, 62 miRNAs) of 314 biomarkers had significantly higher expression in tumor blood samples compared to normal blood samples in at least one cancer type (Figure 3C). For example, MDK was recently reported to be a promising blood biomarker for the diagnosis of liver cancer (35). In BBCancer, we found MDK expression was higher in blood samples of liver cancer patients compared to blood samples of normal persons (fold change >1.5, adjusted P-value <0.05) (Figure 3D). Moreover, MDK expression was also significantly higher in precancerous lesions compared to normal tissues (Figure 3D, fold change >1.5, adjusted P-value <0.05). These results suggest that MDK is an ideal biomarker for the early detection of liver cancer.

By comparing the expression abundances of six different RNA types in blood samples, we found that the expression abundances of tRF-RNAs were highest among the five RNA types in colorectal cancer, suggesting the promising prospects of tRF-RNAs as a blood biomarker for the early detection of colorectal cancers (Figure 3E). To provide a list
of promising blood biomarkers for each cancer type, we further filtered the differentially expressed RNAs using expression abundance. The top 5 differentially expressed RNAs for each RNA type with the highest expression abundance in each cancer are shown (Figure 4). For instance, the expression of *ABCC3* in patients with nonsmall cell lung cancer was potentially correlated with drug resistance (36). The high expression level of exosome *mir-1246* in breast cancer has been reported to be related to breast tumor progression (37). Furthermore, studies on bladder cancer have shown a negative correlation between the high expression of *mir-26a-5p* and patient survival (38). These results suggest that these circulating RNAs may be potential blood biomarkers for related cancers. Overall, the BBCancer database contains a number of clinically relevant potential circulating RNAs that can assist researchers in screening blood molecular markers.

**DISCUSSION**

BB Cancer is a comprehensive open resource for providing the expression landscape of RNA molecules derived from blood samples, including plasma, CTCs and EVs, from cancer patients with various cancer types. Compared to other existing circulating RNA resources, such as exoRbase and EVpedia, BB Cancer is the first database focusing on the expression atlas of RNA molecules in blood samples of cancer patients. Briefly, BB Cancer has the following advantages: (i) BB Cancer contains many types of RNA. Currently, six types of RNA (mRNA,
In conclusion, we believe that BBCancer will be of significant benefit to the community and boost further advances in developing blood-based biomarkers for the early detection of cancer.

ACKNOWLEDGEMENTS

The authors would like to thank Nature Research Editing Service for the editing of language issues.

FUNDING

National Key R&D Program of China [2017YFA0106700]; National Natural Science Foundation of China [91753137, 31471252, 31771462, 81772614, U1611261, 31801105, 81802438]; Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]; Guangdong Natural Science Foundation [2018A030313323]; Science and Technology Program of Guangzhou, China [201604020003 and 201604046001]; Fundamental Research Funds for the Central Universities [SYSU: 19ykpy184]; Funding for open access charge: National Key R&D Program of China [2017YFA0106700]; National Natural Science Foundation of China [91753137, 31471252, 31771462, 81772614, U1611261, 31801105, 81802438]; Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]; Guangdong Natural Science Foundation [2018A030313323]; Science and Technology Program of Guangzhou, China [201604020003 and 201604046001]; Fundamental Research Funds for the Central Universities [SYSU: 19ykpy184].

Conflict of interest statement. None declared.

REFERENCES

1. Cho, H., Mariotto, A.B., Schwartz, L.M., Luo, J. and Woloshin, S. (2014) When do changes in cancer survival mean progress? The insight from population incidence and mortality. J. Natl. Cancer Inst. Monogr., 2014, 187–197.
2. Bardelli, A. and Pantel, K. (2017) Liquid biopsies, what we do not know (yet). Cancer Cell., 31, 172–179.
3. Cohen, J.D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A.A., Wang, F., Mattox, A. et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*, 359, 926–930.

4. No author listed (2018) Early detection: a long road ahead. *Nature Rev. Cancer*, 18, 401.

5. Chu, D., Paolotti, C., Gersch, C., VanDenBerg, D.A., Zabransky, D.J., Cochran, R.L., Wang, H.Y., Toro, P.V., Cidado, J., Croessmann, S. et al. (2016) ESRI mutations in circulating plasma tumor DNA from metastatic breast cancer patients. *Clin. Cancer Res.*, 22, 993–999.

6. Wang, D.-S., Liu, Z.-X., Lu, Y.-X., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J.-H. et al. (2019) Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. *BMJ J.*, 68, 1152–1161.

7. Xu, R.-h., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., Yi, S., Shi, W., Quan, Q., Li, K. et al. (2017) Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. *Nat Mater.*, 16, 1155.

8. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O'Briant, K.C., Allen, A. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. *Proc. Natl. Acad. Sci. U.S.A.*, 105, 10513–10518.

9. Li, Y., Zheng, Q., Bao, C., Li, S., Guo, W., Zhao, J., Chen, D., Gu, J., He, X. and Huang, S. (2013) Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. *Cell Res.*, 25, 981.

10. Hogg, M.C., Raoof, R., El Naggar, H., Monsell, N., Delanty, N., Hogg, M.C. (2016) ESR1 mutations in circulating plasma tumor DNA from short RNA-seq data. *PLoS One.*, 9, e9158.

11. Yang, X., Cheng, Y., Li, L., Wang, Y., Thoburn, C., Lu, Q., Wei, J., Yang, H. and Gu, M. (2015) Detection of stably expressed piRNAs in human blood. *Int. J. Clin. Exp. Med.*, 8, 13353.

12. Kim, D.-K., Kang, B., Kim, O.Y., Choi, D.-S., Lee, J., Kim, S.R., Go, G., Yoon, Y.J., Kim, J.H., Jang, S.C. et al. (2013) EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. *J. Extracell. Vesicles.*, 2, 20384.

13. Li, S., Li, Y., Chen, B., Zhao, J., Yu, S., Tang, Y., Zheng, Q., Li, Y., Wang, P., He, X. et al. (2017) exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res.*, 46, D106–D112.

14. Kodama, Y., Shumway, M., Leinonen, R. and International Nucleotide Sequence Database Collaboration. (2011) The Sequence Read Archive: explosive growth of sequencing data. *Nucleic Acids Res.*, 40, D54–D56.

15. Barrett, T., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Tomashevsky, M., Marshall, K.A., Phillippy, K.H., Sherman, P.M., Holko, M. et al. (2012) NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res.*, 41, D991–D995.

16. Martin, M. (2011) Cutadap removes adapter sequences from high-throughput sequencing reads. *EMBNet journal.*, 17, 10.

17. Kim, D., Langmead, B. and Salzberg, L.S. (2015) HISAT: a fast spliced aligner with low memory requirements. *Nature Methods*, 12, 357–360.

18. Anders, S., Pyl, P.T. and Huber, W. (2015) HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*, 31, 166–169.

19. Wagner, G.P., Kin, K. and Lynch, V.J. (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. *Theory Biosci.*, 131, 281–285.

20. Gao, Y., Wang, J. and Zhao, F. (2015) CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. *Genome Biol.*, 16, 4.

21. Memezak, S., Tash, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S.D., Gregersen, L.H., Munschauer, M. et al. (2013) Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature*, 495, 333.

22. Sai Lakshmi, S. and Agrawal, S. (2007) piRNABank: a web resource on classified and clustered Piwi-interacting RNAs. *Nucleic Acids Res.*, 36, D173–D177.

23. Kent, W.J. (2002) BLAT—the BLAST-like alignment tool. *Genome Res.*, 12, 656–664.

24. Aanes, H., Winata, C., Mohn, L.F., Østrup, O., Mathavan, S., Collins, P., Hogge, T. and Aleström, P. (2014) Normalization of RNA-sequencing data from samples with varying mRNA levels. *PLoS One.*, 9, e89158.

25. Loher, P., Telonis, A.G. and Rigoutsos, I. (2015) MNTbase: a framework for the interactive exploration of mitochondrial and nuclear RNA fragments. *Bioinformatics*, 32, 2481–2489.

26. Pliatsika, V., Loher, P., Telonis, A.G. and Rigoutsos, I. (2016) MINTbase: a framework for the interactive exploration of mitochondrial and nuclear RNA fragments. *Bioinformatics*, 32, 307–315.

27. Lockstone, H.E. (2011) Exon array data analysis using Affymetrix power tools and R statistical software. *Brief. Bioinform.*, 12, 634–644.

28. Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, 15, 550.

29. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W. and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.*, 43, e47.

30. Gautier, L., Cope, L., Bolstad, B.M. and Irizarry, R.A. (2004) affy—analyze of Affymetrix GeneChip data at the probe level. *Bioinformatics*, 20, 307–315.

31. Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, 15, 550.

32. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W. and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.*, 43, e47.

33. Kolde, R., Laur, S., Adler, P. and Vilo, J. (2012) Robust rank aggregation for gene list integration and meta-analysis. *Bioinformatics*, 28, 573–580.

34. Utley, L., Whiteman, B.L., Woods, H.B., Harnan, S., Philips, S.T., Clee, I.A. and Early Cancer Detection Consortium (2016) Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review. *EBioMedicine*, 10, 164–173.

35. Awad, M.M., Naj, A., Obaid, M., Alaa, F., Ahmed, J., Anjum, S. and Janjua, H.A. (2015) Identification of circulating biomarker candidates for hepatocellular carcinoma (HCC): an integrated prioritization approach. *PLoS One.*, 10, e0138913.

36. Mahaffey, C.M., Mahaffey, N.C., Holland, W., Zhang, H., Gandara, D.R., Mack, P.C. and Forman, H.J. (2012) Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. *J. Thorac. Oncol.*, 7, 34–39.

37. Monteforte, A., Am, L., Sherman, M.B., Henderson, K., Sligar, A.D., Spencer, A., Tang, D.B., Dunn, A.K. and Baker, A.B. (2017) Glioblastoma exosomes for therapeutic angiogenesis in peripheral ischemia. *Tissue Eng Part A.*, 23, 1251–1261.

38. Wang, H., Hu, Z. and Chen, L. (2018) Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN. *Oncol Lett.*, 16, 4223–4228.